TRANSCRIPTIONAL ANALYSIS OF ZINC-DEPENDENT HISTONE DEACETYLASES IN SEVERAL HUMAN CANCER CELLS

Authors

  • Yan Li State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, School of Basic Medical Science, Guizhou Medical University, Guiyang 550004, China
  • Yefang Zou State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, School of Basic Medical Science, Guizhou Medical University, Guiyang 550004, China
  • Xiaoxue Chen State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, School of Basic Medical Science, Guizhou Medical University, Guiyang 550004, China
  • Bin He State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, School of Basic Medical Science, Guizhou Medical University, Guiyang 550004, China

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17983

Keywords:

cancer cell lines, HDAC inhibitors, histone deacetylase, transcriptional profile

Abstract

Histone deacetylases, especially zinc-dependent deacetylases HDACs, are among attractive drug targets for treating cancer in recent years. Aim: To explore the expression level of HDACs in several human cancer cell lines and examine the possible association between their expression and the sensitivity/resistance to the selective- or pan-HDAC inhibitors. Materials and Methods: The RNA expression of 11 HDACs isoforms was assayed in HeLa, HepG2, AV3, HEK293, A549, and K562 cells by semiquantitative reverse transcription-polymerase chain reaction. The sensitivity/resistance of these cell lines to the pan- or selective- HDAC inhibitors was estimated by MTS assay. Results: The relative transcription of HDACs genes demonstrated that members of Class I HDAC (HDAC1, 2 and 3) and members of Class II HDAC (HDAC4, 5, 6 and 7) had slight to significant levels of expression in cell lines under study with no dominant HDAC-subtype gene transcription. pan-HDAC inhibitor demonstrated superior antitumor activity compared to HDAC isoform-selective inhibitor. Conclusion: The absence of the dominant HDAC-subtype gene transcription in different human cancer cell lines explains the inferior efficacy of HDAC isoform-selective inhibitors as compared to pan-HDAC inhibitors.

References

De Ruijter AJM, Van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370: 737–49. https://doi.org/10.1042/BJ20021321

Gregoretti I, Lee Y-M, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17–31. https://doi.org/10.1016/j.jmb.2004.02.006

Haigis MC, Guarente LP. Mammalian sirtuins emerging roles in physiology, aging and calorie restriction. Genes Dev 2006; 69: 1702-5. https://doi.org/10.1101/gad.1467506

Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis. Lancet Oncol 2008; 9: 139–48. https://doi.org/10.1016/S1470-2045(08)70004-4

Weichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98: 604–10. https://doi.org/10.1038/sj.bjc.6604199

Sudo T, Mimori K, Nishida N, et al. Histone deacetylase 1 expression in gastric cancer. Oncol Rep 2011; 26: 777–82. https://doi.org/10.3892/or.2011.1361

Oehme I, Deubzer HE, Wegener D, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009; 15: 91–9. https://doi.org/10.1158/1078-0432.CCR-08-0684

West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30–9. https://doi.org/10.1172/JCI69738

Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13: 673–91. https://doi.org/10.1038/nrd4360

Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med 2016; 6: a026831. https://doi.org/10.1101/cshperspect.a026831

Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31–9. https://doi.org/10.1182/blood-2006-06-025999

Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410–7. https://doi.org/10.1182/blood-2006-06-025999

Molife LR, de Bono JS. Belinostat: clinical applications in solid tumors and lymphoma. Expert Opin Investig Drugs 2011; 20: 1723–32. https://doi.org/10.1517/13543784.2011.629604

Libby EN, Becker PS, Burwick N, et al. Panobinostat: a review of trial results and future prospects in multiple myeloma. Expert Rev Hematol 2015; 8: 9–18. https://doi.org/10.1586/17474086.2015.983065

Li Y, Chen K, Zhou Y, et al. A new strategy to target acute myeloid leukemia stem and progenitor cells using chidamide, a histone deacetylase inhibitor. Curr Cancer Drug Targets 2015; 15: 493–503. https://doi.org/10.2174/156800961506150805153230

Li Y, Woster PM. Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group. MedChemComm 2015; 6: 613–8. https://doi.org/10.1039/C4MD00401A

Clawson GA. Histone deacetylase inhibitors as cancer therapeutics. Ann Transl Med 2016; 4: 287. https://doi.org/10.21037/atm.2016.07.22

Suzuki T, Miyata N. Non-hydroxamate histone deacetylase inhibitors. Curr Med Chem 2005; 12: 2867–80. https://doi.org/10.1016/j.phrs.2018.03.001

Ouaïssi M, Cabral S, Tavares J, et al. Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. Cancer Biol Ther 2008; 7: 523–31. https://doi.org/10.4161/cbt.7.4.5480

Nakagawa M, Oda Y, Eguchi T, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007; 18: 769–74. https://doi.org/10.3892/or.18.4.769

Fu W, Wu K, Duan J. Sequence and expression analysis of histone deacetylases in rice. Biochem Biophys Res Commun 2007; 356: 843–50. https://doi.org/10.1016/j.bbrc.2007.03.010

Waltregny D, North B, Van Mellaert F, et al. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem 2004; 48: 273–90. PMID: 15590418

Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001; 92: 1300–4. https://doi.org/10.1111/j.1349-7006.2001.tb02153.x

Ning ZQ, Li ZB, Newman MJ, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol 2012; 69: 901–9. https://doi.org/10.1007/s00280-011-1766-x

Bondarev AD, Attwood MM, Jonsson J, et al. Recent developments of HDAC inhibitors: Emerging indications and novel molecules. Br J Clin Pharmacol 2021; 87: 4577–97. https://doi.org/10.1111/bcp.14889

Downloads

Published

26.05.2023

How to Cite

Li, Y., Zou, Y., Chen, X., & He, B. (2023). TRANSCRIPTIONAL ANALYSIS OF ZINC-DEPENDENT HISTONE DEACETYLASES IN SEVERAL HUMAN CANCER CELLS. Experimental Oncology, 44(2), 126–131. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17983

Issue

Section

Original contributions